Background: Phosphorylase kinase (PhK) activity is induced by injurious stimuli, which is known to precipitate psoriasis. We had previously reported that elevated PhK activity in psoriatic epidermis correlated with increased psoriatic activity, and that suppression of PhK activity by its inhibitor, curcumin gel, correlated with disease resolution. Objective: We evaluated the efficacy of a strat...

INTRODUCTION Demographic and disease characteristics may impact response to psoriasis therapies. The objective of this study is to explore the safety and efficacy profile of secukinumab in North American (NA) versus non-NA patients with moderate to severe psoriasis. METHODS Data were pooled from four phase 3 studies of secukinumab. Secukinumab (300 and 150 mg) was administered at baseline, we...

INTRODUCTION Ischemia-modified albumin (IMA), a novel ischemia marker, and mean platelet volume (MPV), a determinant of platelet activation, have been reported as elevated markers in cardiovascular risk factors such as atherosclerosis, metabolic syndrome, diabetes mellitus (DM), hypertension, and dyslipidemia. As psoriasis is a chronic inflammatory disease having comorbidities, IMA and MPV can ...

Background: Psoriasis is a chronic inflammatory skin disease that is estimated to affect 0.6% to 4.8% of the general population. The optimum number of NB-UVB phototherapy sessions is yet to be determined. The aim of this study was to compare therapeutic effects of NB-UVB in treating chronic plaque type psoriasis three times weekly vs. five times weekly. Materials and Methods: This study was des...

Objective: The aim of this study is to assess the neutrophil lymphocyte ratio (NLR) as an inflammatory marker in patients with psoriasis and to compare it with healthy subjects and to evaluate the correlation with the severity of the disease. Methods: 104 psoriasis patients and 70 healthy persons were included as the control group. The laboratory results were recorded retrospectively from the p...

decisions. Because severity scorings differed mainly in diverse estimations of the involved area and induration of the lesions, one may speculate that the divergence might have resulted from the inability of the teledermatologists to see the entire body and to palpate the lesions, or it might have resulted from some flaws of the PASI scoring system for which an interrater variability of up to 8...

Tofacitinib is an oral Janus kinase inhibitor. An integrated analysis was conducted to evaluate dosage optimality for tofacitinib in patients with moderate-to-severe plaque psoriasis and the impact of body weight on optimality in this patient population. Data were pooled from one phase IIb trial (2, 5, and 15 mg twice daily (b.i.d.)) and four phase III trials (5 and 10 mg b.i.d.). A longitudina...